Pfizer (PFE) has matched Novo Nordisk’s (NVO) offer to buy weight-loss drug start-up Metsera (MTSR) for up to $10B, Financial Times’ Oliver Barnes, James Fontanella-Khan, and Patrick Temple-West report. Pfizer submitted its sweetened bid, which matches Novo’s offer from Tuesday valuing Metsera at $86.20 a share, ahead of a deadline on Wednesday, keeping it in the race for the anti-obesity biotech, according to two people familiar with the matter.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer plans to sweeten offer for Metsera, WSJ reports
- Pfizer says ‘we remain confident in the merits of our claims’ against Metsera
- Novo Nordisk tells STAT Metsera deal structure ‘consistent with antitrust laws’
- Metsera says will accept superior bids until closing, Bloomberg reports
- Metsera falls after FTC raises filing concerns over Novo bid